Additional European Equity News

AstraZeneca (AZN LN) - Positive high-level results from an interim analysis of the AMPLIFY Phase III trial for untreated adult patients with chronic lymphocytic leukaemia (CLL). (AstraZeneca)

Entain (ETN LN) - BetMGM sees higher Y/Y revenue growth for H2 2024 into 2025. H2 EBITDA to be similar to H1. H1 Net revenue +6% Y/Y, Q2 Net revenue +3% Q/Q, Q2 online sports betting NGR per active +16% Y/Y. Q2 iGaming average monthly actives +18% Y/Y, up from 9% in 1Q, with no new state launches. (Yahoo Finance)

EssilorLuxottica (EL FP) - Co. announced the launched of a share buyback programme of up to 4mln shares to last from July 29th 2024 to October 29th 2025. (Newswires)

GSK (GSK LN) - Arexvy, GSK’s Respiratory Syncytial Virus (RSV) vaccine, receives positive European Medicines Agency CHMP opinion for adults aged 50-59 at increased risk for RSV disease. (GSK)

Heineken (HEIA NA) - CEO said Europe had a disappointing June and July as the expected upside related to sports events did not materialise; CR Beer impairment had nothing to do with quarterly performance. (Newswires)

Pearson (PSN LN) - Proposes interim dividend of 7.4 pence; notes of no changes to 2024 and 2025 guidance. (Newswires)

Pershing Square Holdings (PSH LN) - Pershing Square USA IPO price will be USD 50 per common share; date of pricing to be announced. (Newswires)

Thyssenkurpp (TKA GY)/Nucera (NCH2 GY) - Nucera Q3 (EUR): EBIT 6mln (prev. 7mln). Sales 236mln (prev. 188mln). Co. says communicated sales and earnings expectations for alkaline water electrolysis business is not being sustained. (Newswires) 

Volkswagen (VOW3 GY) - Lamborghini H1 (EUR): Operating profit 458mln (prev. 456mln). Revenue +14.1% Y/Y. Deliveries +4% Y/Y. (Newswires)

BAE Systems (BA/ LN) upgraded to Buy from Neutral at Citi

Eni (ENI IM) upgraded to Outperform from Sector Perform at RBC

29 Jul 2024 - 07:27- EquitiesResearch Sheet- Source: Newsquawk